scholarly journals Proteínas importantes para la invasión de Babesia bovis a las células huésped

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Laura Esperanza Cuy Chaparro ◽  
Anny Camargo Mancipe ◽  
Alida Marcela Gómez Rodríguez ◽  
César Reyes Santofimio ◽  
Darwin Andrés Moreno Pérez
Keyword(s):  
Babesia Bovis ◽  
Invasion Process ◽  
Vaccine Candidates

Introducción. La babesiosis bovina es causada por parásitos Apicomplexa del género Babesia, siendo Babesia bovis la especie asociada con cuadros clínicos más graves de la enfermedad. La invasión de B. bovis a los eritrocitos bovinos implica la interacción entre moléculas de los merozoítos del parásito con receptores de las células huésped. Por ende, conocer las proteínas involucradas en este proceso supone un importante paso para entender la biología del parásito. Objetivo. Describir las principales moléculas implicadas en el proceso de invasión de B. bovis a eritrocitos bovinos. Metodología. Se realizó una búsqueda en NCBI, Medline, LILACS y SciELO usando los términos: “Babesia bovis AND invasion process”, “MSA-1”, “RON2”, “AMA-1”, “moving junction”, “B. bovis AND Vaccine candidates”. 61 publicaciones disponibles en inglés que describen el estudio de las anteriores proteínas y su participación en la invasión los cuales han sido publicados hasta mayo 2020 se revisaron completamente. Resultados: Siendo el proceso de invasión a eritrocitos bovinos clave para la patogénesis de la babesiosis bovina, se hizo una revisión donde se encontraron 3 proteínas de B. bovis que participan en el reconocimiento e invasión a las células diana: MSA-1, AMA-1 y RON2. Sin embargo, los detalles a nivel molecular para las interacciones inter e intramoleculares aún no se han dilucidado por completo. Conclusiones. Conocer las moléculas involucradas en las interacciones parásito-hospedero permitirá comprender cómo ocurre el proceso de invasión de B. bovis a los eritrocitos y así evaluar su futura utilidad como componente de una estrategia de control efectiva contra esta parasitosis.

scholarly journals Babesia bovis: Actualidad del desarrollo de una vacuna

2019 ◽  
Vol 6 (2) ◽  
pp. 182-199
Author(s):  
Laura Esperanza Cuy Chaparro ◽  
Laura Alejandra Ricaurte Contreras ◽  
Anny Jineth Camargo Mancipe ◽  
Darwin Andrés Moreno Pérez
Keyword(s):  
Babesia Bovis ◽  
Vaccine Candidates

Introducción. Babesia bovis es el principal agente causal de la babesiosis bovina, una importante enfermedad veterinaria transmitida por garrapatas a nivel mundial. Las estrategias convencionales para controlar esta parasitosis han presentado múltiples limitaciones por lo que el desarrollo de una vacuna basada en antígenos representa una estrategia apropiada para la prevención y el tratamiento. Objetivo. Describir los aspectos relevantes del ciclo de vida del parásito B. bovis, la epidemiología, diagnóstico y la aplicación de diferentes estrategias usadas para controlar esta parasitosis. Además, se discuten potenciales puntos de intervención para desarrollar una vacuna contra este parásito. Metodología. Se realizó una búsqueda en las bases de datos usando los términos: “Babesia bovis AND lyfe cycle”, “B. bovis vaccine and Vaccine candidates”, entre otras. Los estudios con mayor pertinencia publicados hasta la actualidad se revisaron completamente. Resultados: Los detalles de la biología de parásito B. bovis y el proceso molecular usado para ocasionar la enfermedad en el hospedador son poco conocidos, lo que explica que el desarrollado de estrategias para el control de esta parasitosis no hayan sido del todo eficientes. Por lo tanto, se requiere diseñar nuevas medidas, por ejemplo, desarrollar vacunas de nueva generación basadas en un enfoque funcional que permitan mejorar las condiciones de sanidad animal. Conclusiones. Comprender el complejo ciclo de vida de B. bovis permitirá estudiar las interacciones huésped-parásito-garrapata e identificar moléculas implicadas en la adhesión/invasión celular para evaluar su utilidad como componente de una vacuna que controle esta parasitosis.

Immunoproteomics Approach for Screening of Vaccine Candidates against Intestinal Botulism

2017 ◽  
Vol 24 (8) ◽  
Author(s):  
Arti Sharma ◽  
Sarita Rani ◽  
Syed Imteyaz Alam ◽  
Sarkaraisamy Ponmariappan
Keyword(s):  
Vaccine Candidates

B-Cells and the Use of Non-Human Primates for Evaluation of HIV Vaccine Candidates

2015 ◽  
Vol 13 (6) ◽  
pp. 462-478 ◽  
Author(s):  
Thorsten Demberg ◽  
Marjorie Robert-Guroff
Keyword(s):  
B Cells ◽  
Hiv Vaccine ◽  
Vaccine Candidates

Prediction of Prophylactic Peptide Vaccine Candidates for Human Papillomavirus (HPV): An Immunoinformatics and Reverse Vaccinology Approach

2020 ◽  
Vol 17 ◽  
Author(s):  
Mehreen Ismail ◽  
Zureesha Sajid ◽  
Amjad Ali ◽  
Xiaogang Wu ◽  
Syed Aun Muhammad ◽  
...  
Keyword(s):  
T Cells ◽  
Human Papillomavirus ◽  
T Cell ◽  
Binding Affinity ◽  
Cd8 T Cells ◽  
Reverse Vaccinology ◽  
Host Immune System ◽  
T Cell Epitopes ◽  
Multiple Alleles ◽  
Vaccine Candidates

Background: Human Papillomavirus (HPV) is responsible for substantial morbidity and mortality worldwide. We predicted immunogenic promiscuous monovalent and polyvalent T-cell epitopes from the polyprotein of the Human Papillomavirus (HPV) using a range of bioinformatics tools and servers. Methods: We used immunoinformatics and reverse vaccinology-based approaches to design prophylactic peptides by antigenicity analysis, Tcell epitopes prediction, proteasomal and conservancy evaluation, host-pathogen protein interactions, and in silico binding affinity analysis. Results: We found two early proteins (E2 and E6) and two late proteins (L1 and L2) of HPV as potential vaccine candidates. Of these proteins (E2, E6, L1 & L2), 2-epitopes of each candidate protein for multiple alleles of MHC class I and II bearing significant binding affinity (>-6.0 kcal/mole). These potential epitopes for CD4+ and CD8+ T-cells were also linked to design polyvalent construct using GPGPG linkers. Cholera toxin B and mycobacterial heparin-binding hemagglutinin adjuvant with a molecular weight of 12.5 and 18.5 kDa were used for epitopes of CD4+ and CD8+ T-cells respectively. The molecular docking indicated the optimum binding affinity of HPV peptides with MHC molecules. This interaction showed that our predicted vaccine candidates are suitable to trigger the host immune system to prevent HPV infections. Conclusion: The predicted conserved T-cell epitopes would contribute to the imminent design of HPV vaccine candidates, which will be able to induce a broad range of immune-responses in a heterogeneous HLA population.

A multi-method and structure-based in silico vaccine designing against Helicobacter pylori employing immuno-informatics approach

2020 ◽  
Vol 17 ◽  
Author(s):  
Anam Naz ◽  
Tahreem Zaheer ◽  
Hamza Arshad Dar ◽  
Faryal Mehwish Awan ◽  
Ayesha Obaid ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Vaccine Development ◽  
Amino Acid Sequences ◽  
The Body ◽  
New Drugs ◽  
Toll Like Receptor ◽  
Peptide Vaccines ◽  
Hla Alleles ◽  
Vaccine Candidates ◽  
H Pylori

Background: Helicobacter pylori infection and its treatment still remains a challenge to human health worldwide. A variety of antibiotics and combination therapies are currently used to treat H. pylori induced ulcers and carcinoma; however, no effective treatment is available to eliminate the pathogen from the body. Additionally, antibiotic resistance is also one of the main reasons for prolonged and persistent infection. Aim of the study: Until new drugs are available for this infection, vaccinology seems the only alternative opportunity to exploit against H. pylori induced diseases. Methods: Multiple epitopes prioritized in our previous study have been tested for their possible antigenic combinations, and results in 169-mer and 183-mer peptide vaccines containing the amino acid sequences of 3 and 4 epitopes respectively, along with adjuvant (Cholera Toxin Subunit B adjuvant at 5’ end) and linkers (GPGPG and EAAAK). Results: Poly-epitope proteins proposed as potential vaccine candidates against H. pylori include SabAHP0289-Omp16-VacA (SHOV), VacA-Omp16-HP0289-FecA (VOHF), VacA-Omp16-HP0289-SabA (VOHS), VacA-Omp16-HP0289-BabA (VOHB), VacA-Omp16-HP0289-SabA-FecA (VOHSF), VacAOmp16-HP0289-SabA-BabA (VOHSB) and VacA-Omp16-HP0289-BabA-SabA (VOHBS). Structures of these poly-epitope peptide vaccines have been modelled and checked for their affinity with HLA alleles and receptors. These proposed poly-epitope vaccine candidates bind efficiently with A2, A3, B7 and DR1 superfamilies of HLA alleles. They can also form stable and significant interactions with Toll-like receptor 2 and Toll-like receptor 4. Conclusion: Results suggest that these multi-epitopic vaccines can elicit a significant immune response against H. pylori and can be tested further for efficient vaccine development.

Outbreak of coronavirus disease 2019 (COVID-19) and its manifestation

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Bikash Debnath ◽  
Waikhom Somraj Singh ◽  
Kuntal Manna
Keyword(s):  
Antiviral Drug ◽  
World Health ◽  
Family Welfare ◽  
Pregnant Mother ◽  
Vaccine Candidates ◽  
The World ◽  
Mode Of Transmission ◽  
Health Organization ◽  
Effective Drugs ◽  
Respiratory Droplets

: The coronavirus disease 2019 (COVID-19) first outbreak in Wuhan, China, and the infection is intense worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19. The World Health Organization (WHO) confirmed total deaths had noted 4.20% globally (March 21, 2020). Between the intervals of four months (July 21, 2020), confirmed total deaths had recorded 4.17%, globally. In India, 909 confirmed cases and 19 deaths were reported by Health and Family Welfare, Government of India, March 28, 2020. Between the intervals of 123 days In India, 1638870 confirmed cases and 35684 deaths. COVID-19 can potentially spread from person to person through direct contact or respiratory droplets from coughing and sneezing. The most common symptoms are fever, dry cough, difficulty in breathing, and fatigue. A pregnant mother with COVID-19 has fewer chances to transfer this infection of her newborn babies. Children have less affected than an adult. A specific antiviral drug or vaccine has not been developed to cure the disease. Chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, nitazoxanide, and remdesivir have effective drugs to treat COVID-19. Many vaccine candidates are under pre-clinical and clinical studies. In this review, we highlight the epidemiology, sign-symptoms, pathogenesis, mode of transmission, and effects of a pregnant mother with newborns, children, prevention, and drugs affective to COVID-19.

Sign in / Sign up

Export Citation Format

Share Document